ARTICLE | Clinical News

Aubagio teriflunomide regulatory update

October 27, 2014 7:00 AM UTC

FDA approved an sNDA to update the label of Aubagio teriflunomide from Sanofi's Genzyme Corp. unit to treat relapsing multiple sclerosis to include data from the double-blind, international Phase III TOWER and TOPIC trials. The dihydroorotate dehydrogenase (DHODH) inhibitor is approved in more than 50 countries, including the U.S., Australia, Switzerland, Canada and those of the EU. ...